New cell therapy shows promise for Hard-to-Treat blood cancer

NCT ID NCT04674813

Completed Disease control Sponsor: Juno Therapeutics, a Subsidiary of Celgene Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 23, 2026 · Updated 18 times

Summary

This early-stage trial tested a new treatment called CC-95266 in 130 adults with multiple myeloma that had come back or stopped responding to other therapies. The main goals were to check safety, find the right dose, and see if the treatment could shrink the cancer. While not a cure, it aims to control the disease in people with few options left.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Local Institution - 001

Nashville, Tennessee, 37203, United States
Local Institution - 002

Denver, Colorado, 80218, United States
Local Institution - 003

Seattle, Washington, 98104, United States
Local Institution - 005

Birmingham, Alabama, 10016, United States
Local Institution - 006

Dallas, Texas, 75390, United States
Local Institution - 008

Baltimore, Maryland, 21201, United States
Local Institution - 009

Duarte, California, 91010-301, United States
Local Institution - 010

Boston, Massachusetts, 02215, United States
Local Institution - 011

New York, New York, 10029, United States
Local Institution - 012

San Francisco, California, 94143, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA